Bexarotene Therapy

Chicago - Results of two clinical trials involving bexarotene (Targretin) and presented at recent meetings of the American Academy of Dermatology offer hope for patients with severe forms of psoriasis refractory to systemic therapies, according to researchers.

Related Videos
Related Content

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023
Advertise
Contact Us
Job Board
Do Not Sell My Information
Terms and Conditions
Privacy Policy
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.